Subcutaneous in vivo tumor growth following injection of parental or gene-modified tumor cells.

(A) Growth of unmodified parental NXS2 (-▪-); NXS2-I-GFP (-●-); NXS2-TIMP-3-I-GFP-(low) (-▵-); or NXS2-TIMP-3-I-GFP-(high) (-▴-) tumor cells in C.B-17 SCID mice (n = 10 mice/group). *P < .0001 comparing NXS2-TIMP-3-I-GFP-(low) with NXS2-I-GFP; **P < .002 comparing NXS2-TIMP-3-I-GFP-(high) with NXS2-TIMP-3-I-GFP-(low). Shown also is a Western blot for TIMP-3 expression in protein lysates of tumors from NXS2-I-GFP (a,c), NXS2-TIMP-3-I-GFP-(low) (d,e), and NXS2-TIMP-3-I-GFP-(high) (f,g). Lane b has recombinant TIMP-3. (B) Growth of unmodified parental B16F10 (-▪-); B16F10-I-GFP (-●-); or B16F10-TIMP-3-I-GFP (-○-) tumor cells in C.B-17 SCID mice (n = 10 mice/group). P < .001 comparing B16F10-TIMP-3-I-GFP with B16F10-I-GFP. Error bars represent SE.